A patient with chronic urticaria unresponsive to cetirizine 10 mg twice daily is to be escalated. According to the EAACI urticaria guidelines, the next step is:
- A Increase cetirizine to up to 4× the licensed dose (40 mg/day) before adding omalizumab ✓
- B Add a H2 antihistamine (famotidine) — combined H1+H2 blockade maximally saturates histamine receptors
- C Switch to a first-generation H1 antihistamine (chlorpheniramine) for superior CNS sedation and itch suppression
- D Add ciclosporin as the second-line agent after standard-dose second-generation antihistamines fail
Explanation
EAACI/GA2LEN/EDF/WAO urticaria guidelines recommend a stepwise approach: Step 1 — second-generation H1 antihistamine at standard dose; Step 2 — updosing to 4× the standard licensed dose (off-label but evidence-based, as cetirizine, loratadine, or bilastine at higher doses provide better H1 occupancy without significant sedation); Step 3 — add omalizumab (anti-IgE monoclonal antibody, approved for chronic spontaneous urticaria); Step 4 — ciclosporin. First-generation antihistamines have inferior H1 receptor selectivity, high anticholinergic burden, and sedation, and are not recommended as upgrades. H2 blockers add minimal benefit in isolation.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.